Strides receives USFDA approval for Triamcinolone Acetonide Cream

Deepthi | Myequity news | Date : 13-02-2019 09:30:00 IST

Strides Pharma Global Pte. Limited, Singapore, has received approval for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. from the United States Food & Drug Administration (US FDA). The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.

According to IQVIA MAT data, the US market for Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5%. is approximately US$ 55 Mn. The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.

About Triamcinolone Acetonide Cream

Triamcinolone Acetonide Cream is used to treat a variety of skin conditions including treatment of eczema, dermatitis, allergies, rash and helps in reducing swelling, itching, and redness that can occur in these types of conditions.

About Strides

Strides, is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor‐funded markets. The Company’s global manufacturing sites are located in India‐ Bangalore (two sites), Pondicherry, and Chennai, Singapore, Italy‐ Milan, and Kenya‐ Nairobi.

More from Myequity